Organization | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias Report issue

Academic/Hospital Phase 2

Founded: Barcelona Spain (1988)

Organization Overview

First Clinical Trial

1998

NCT01716793

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Alternative names

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Active Ingredients

Drugs in Phase 2 Trials (9)

allogeneic stem cells (1 trial)

autologous cd34+ cells (2 trials)

autologous mononuclear stem cell (2 trials)

clofarabine (clolar) (1 trial)

cytarabine (cytosar-u) (4 trials)

gemtuzumab ozogamicin (mylotarg) (2 trials)

hla-identical stem cells (1 trial)

idarubicin (idamycin) (2 trials)

sargramostim (leukine) (1 trial)

Drugs in Other Trials (1)

Filgrastim (neupogen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 10